TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00887172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jing Fang Bai Du san
Description: The Jing Fang Bai Du san can relieve external symptoms and effectively clear up the pathogenic cold. It contains 13 herbs including, Radix Angelicae Pubescentis, Radix Peucedani, Radix Ginseng, Smilacis Glabrae Rhizoma, Rhizoma Chuanxiong, Fructus Aurantii, Radix Platycodi, GlycyrrhizaeRadix, Herba Schizonepetae, Fructus Arctii, MenthaeFolium, Radix Saposhnikoviae, Rhizoma et Radix Notopterygii.The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The sachets of the CHM formulae and placebo were identical in appearance except for the randomization numbers. The placebo contains Maltose-dextrine granules that are identical in weight, appearance, flavour and texture as the CHM granules. Both the Chinese medicine practitioner who assessed the subjects and the subjects were blinded to the nature of the treatment. The pharmaceutical supplier kept the medication and placebo codes, which were broken at the end of the study after completion of all the assessment and data analyses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The sachets of the CHM formulae and placebo were identical in appearance except for the randomization numbers. The placebo contains Maltose-dextrine granules that are identical in weight, appearance, flavour and texture as the CHM granules. Both the Chinese medicine practitioner who assessed the subjects and the subjects were blinded to the nature of the treatment. The pharmaceutical supplier kept the medication and placebo codes, which were broken at the end of the study after completion of all the assessment and data analyses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ying Qiao san
Description: The Ying Qiao san can relieve external symptoms and effectively clear up the pathogenic heat. It contains 10 herbs: Fructus Forsythiae, LoniceraeFlos, Radix Platycodi, MenthaeFolium, GlycyrrhizaeRadix, Herba Schizonepetae, Sojae Semen praeparatum, Fructus Arctii, PhragmitisRhizoma and LophatheriHerba. The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
Study: NCT02678546

Intervention type: OTHER
Intervention: Other
Description: case review of diagnosed disease
Study: NCT03858751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTM1201AT
Description: LTM1201AT oral capsule before sleep

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTM1201AG
Description: LTM1201AG oral capsule before sleep
Study: NCT02316145

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Habilitation (Internet-based support and coaching)
Description: Support and coaching with therapist (psychologist or educational therapist) by using chat and e-mail
Study: NCT03858751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTM1201AD
Description: LTM1201AD oral capsule before sleep
Study: NCT03407352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Video Game Play
Description: 60 minutes of active video game play at a moderate intensity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Passive Video Game Play
Description: 60 minutes of passive video game play
Study: NCT00875953

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard neck dissection
Description: standard surgical technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel Dissection
Description: harmonic scalpel used for neck dissection after flaps are raised.
Study: NCT03832946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB0139
Description: GB0139 is a galectin-3 inhibitor designed to modulate the fibrogenic response to tissue injury. It is administered as inhalation once a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered as inhalation once a day
Study: NCT00724971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin (CMC-544)
Description: 1.8 mg/m2, IV on day 2 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab (Rituxan)
Description: 375 mg/m2, IV on day 1 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
Study: NCT03095989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: The structure of the protocol incorporates key features of Langer's mindfulness theory. Many of the tasks and exercises have demonstrated increased mindfulness in the general population and have been modified to incorporate ALS-specific exercises that make sense from patients and caregivers' points of view. The intervention provides easily understood multimedia (video and written) presentations of the framework of mindfulness and the aims of the planned tasks. The general structure of the protocol mixes different mindfulness elements; for every week there is a specific topic examined in depth. These topics are: Attention to variability; Positive and negative events; Unpredictability; Sense Making; and Novelty seeking / novelty producing. The overall duration of the protocol is 5 weeks.
Study: NCT04170192

Intervention type: PROCEDURE
Intervention: Cord Blood Stem Cell Transplantation
Description: Unrelated cord blood stem cell selection; Reduced intensity conditioning regime; GVHD prevention; Infection prevention.
Study: NCT00755586

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mononuclear cell injection: 4 * 10e8 cells
Description: 350 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 4 \* 10e8 cells in the m. biceps brachii.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mononuclear cell injection: 8 * 10e8 cells
Description: 650 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 8 \* 10e8 cells in the m. biceps brachii.

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: No mononuclear cell injection
Description: Patients will receive a muscle tendon transposition surgery without bone marrow aspiration or mononuclear cell injection.
Study: NCT05446415

Intervention type: OTHER
Group type: OTHER
Intervention: Analyze basal expression incretin for immunolabeling and mRNA expression glucagon-like secretion peptide-1 (GLP-1) and peptide YY (PYY 3-36) incretins by L cells.
Description: Preoperative and postoperative
Study: NCT02948985

Intervention type: OTHER
Intervention: treated with FOLFIRI±cetuximab
Description: Peripheral blood samples of 10 mL were collected from the patients for CTCs analysis and tumor marker in every cycle D0 and D8. Tumor response evaluation will be performed after four cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastatic organ, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.The correlation of the RAS status on CTCs and the mutant gene in ctDNA to the therapeutic response will be evaluated.
Study: NCT04695301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation protocol through a digital platform
Description: During 3 months the patients will participate in a rehabilitation program through a digital platform

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation protocol through a digital platform
Description: During 3 months the patients will participate in a rehabilitation program through a digital platform
Study: NCT03250962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD-1 monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD-1 monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
Study: NCT00560833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esmirtazapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esmirtazapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esmirtazapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esmirtazapine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04533841

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: Pt will receive misoprostol for labor induction then after 30 minutes will receive ether propranolol or misoprostol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Pt will receive misoprostol for labor induction then after 30 minutes will receive ether propranolol or misoprostol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol
Study: NCT03644979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skydiving
Description: Tandem skydiving (with an experienced instructor)
Study: NCT04793321

Intervention type: DEVICE
Group type: OTHER
Intervention: Baby carrier
Description: * It is made in china.~* It is made of Cotton-Polyester.~* It has 3 belts - 2 shoulder belts and one waist belt for superior lumbar support. Shoulder straps are padded and adjustable for the parent's comfort. It has webbing straps for shoulder and waist strap adjustment.~* It is suitable for newborn to 12-months baby~* It is available online at babyshopstores https://www.babyshopstores.com/

Intervention type: DEVICE
Group type: OTHER
Intervention: Biodex Balance System
Description: * The Biodex Balance System SD (The Biodex Balance System SD Model 945-300, 115 VAC, Shirley, NY, USA) is used to assess the balance in this study.~* It is an objective device that measures dynamic postural stability. It uses a circular platform that allows up to 20˚of of platform tilt in a 360˚ range of motion.~* The measures of postural stability score for BBS are the Overall Stability Index (OSI), Medial-Lateral Stability Index (MLSI), and Anterior-Posterior Stability Index (APSI). These indices are standard deviations that assess the path of sway around the zero point from the center of the platform and are measured in degrees. A high score in these stability indices indicates poor balance.

Intervention type: OTHER
Group type: OTHER
Intervention: Infant mannequin
Description: The mannequin infant has 3 Kg which corresponds to the infant's age from birth until 1month. This weight is selected as it corresponds to the age at which the infants are frequently carried by the mother .

Intervention type: DEVICE
Group type: OTHER
Intervention: Biodex gait trainer 2 TM
Description: Gait Trainer 2™ ( model number:950-385, 115 VAC 50/60 Hz, made in the USA) is used for participants to walk on as walking is one of the most common daily life activities. because caregivers commonly walk while carrying their infants as it has a calming effect on crying infants~It consists of :~* Display: Use Audio and Visual Biofeedback - real-time biofeedback prompts patients into a proper gait pattern.~* Heart Rate Monitoring~* Handrail~* Open Platform
Study: NCT02359721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tablet clarithromycin 500 mg (Clarino-500) orally
Description: orally
Study: NCT03900936

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological tests
Description: This study is not an intervention as such. We are simply comparing the scores of MCI patients who subsequently went on to develop dementia vs those who did not.
Study: NCT01194141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: aerobic exercise training, 45-60 minutes, 3x/week, 12 weeks (3-months)
Study: NCT02717793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength testing
Description: isometric muscle strength~1RM measurement of muscle strength

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength testing
Description: isometric muscle strength~1RM measurement of muscle strength
Study: NCT02467777

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bair Hugger

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VitaHeat
Study: NCT00893659

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: wheat bread with beta-glucan
Description: 3 g beta-glucan in approximately 200 g of wheat bread per day for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: wheat bread without beta-glucan
Description: Approximately 200 g of wheat bread (without beta-glucan supplementation) per day for 3 months
Study: NCT04497701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF group
Description: Patients received a single dose of 100 ug/kg of PEG-rhG-CSF（Jinyouli®）, on the basis of actual body weight. Peg-rhG-CSF can be used prophylactically only when the interval between two chemotherapy regimens is no less than 12 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhG-CSF group
Description: Patients received 5μg/kg/d of rhG-CSF, on the basis of actual body weight.
Study: NCT03510481

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: PfSPZ Vaccine is Radiation attenuated, aseptic, purified, vialed, cryopreserved, NF54 P. falciparum sporozoites produced by Sanaria, Inc.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: PfSPZ Vaccine is Radiation attenuated, aseptic, purified, vialed, cryopreserved, NF54 P. falciparum sporozoites produced by Sanaria, Inc.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Clear liquid indistinguishable from the study product will be used as a placebo rather than a comparator vaccine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Clear liquid indistinguishable from the study product will be used as a placebo rather than a comparator vaccine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether 20mg/lumefantrine 120mg (AL)
Description: Licensed antimalarial in the US and Mali for use for uncomplicated malaria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether 20mg/lumefantrine 120mg (AL)
Description: Licensed antimalarial in the US and Mali for use for uncomplicated malaria.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: artemether 20mg/lumefantrine 120mg (AL)
Description: Licensed antimalarial in the US and Mali for use for uncomplicated malaria.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: artemether 20mg/lumefantrine 120mg (AL)
Description: Licensed antimalarial in the US and Mali for use for uncomplicated malaria.
Study: NCT03041610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking intervention
Description: The intervention will be delivered over a six-month period and will consist of: (1) an individualized pedometer-based walking program with weekly step goals, (2) regular visits to the clinic including face-to-face session with the physician, and (3) regular telephone calls with the research nurse in between the face-to-face contacts.
Study: NCT01842789

Intervention type: DEVICE
Group type: OTHER
Intervention: Acessa Procedure
Description: Acessa Procedure

Intervention type: DEVICE
Group type: OTHER
Intervention: Acessa Procedure
Description: Acessa Procedure
Study: NCT00949026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus (Torisel)
Description: Dose de-escalation dependent on microdialysis results
Study: NCT01081977

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early Cord Clamping
Description: Early Umbilical Cord Clamping (Clamping of Umbilical Cord within 30 seconds of shoulder delivery of neonate)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed Cord Clamping
Description: Delayed Umbilical Cord Clamping (Clamping Umbilical Cord after 2 minutes of shoulder delivery of neonate
Study: NCT03588572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine hydrochloride capsules
Description: The patients in venlafaxine group begin to take the venlafaxine hydrochloride capsules after the first visitation(the first day after randomization), each containing venlafaxine 75mg, 1 capsule per day, until 4 weeks after randomization
Study: NCT00450424

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: counseling intervention
Description: Participants in the Counseling intervention will meet with the study health educator who will provide the participant with the standard MSI informed consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. The patients will either sign (or not sign, if they do not consent to have the test, or wish to think further about the decision) after this discussion. Participants who have further questions will be referred to either the attending physician or the genetics counselor at each hospital site.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: CD-ROM intervention
Description: Participants who are randomized to the CD-ROM condition will complete the baseline interview and then meet with the health educator who will provide the participant with the standard MSI consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. Next, the participant will be provided with the CD-ROM to view on a laptop computer in the clinic. Participants will also be given a copy of the CD-ROM to take home and keep for future reference. The CD-ROM patients will sign (or not sign, if they do not consent or wish to think further about the decision) the consent form after this discussion.
Study: NCT00850616

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V526
Description: 0.5 mL intramuscular injections of MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4 and Week 26.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V526
Description: 0.5 mL intramuscular injections of MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4 and Week 26.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V526
Description: 0.5 mL intramuscular injections of MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4 and Week 26.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V526
Description: 0.5 mL intramuscular injections of MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4 and Week 26.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V526
Description: 0.5 mL intramuscular injections of MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4 and Week 26.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V526
Description: 0.5 mL intramuscular injections of MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4 and Week 26.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V526
Description: 0.5 mL intramuscular injections of MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4 and Week 26.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo to V526
Description: 0.5 mL intramuscular injections of placebo to MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4, and Week 26.
Study: NCT02863991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: 375 mg or 625 mg ONC201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: 375 mg or 625 mg ONC201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg dexamethasone
Study: NCT00149773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy
Study: NCT00951717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral education intervention
Description: One education session with a social worker while at the hospital, provision of an educational pamphlet and summary sheet for partner, a needs assessment by the social worker 2 weeks after hospital discharge, and additional patient education and reinforcement of self-management skills, as needed
Study: NCT00089310

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: technetium-99
Description: 0.25 mCi in 4 equal doses
Study: NCT04647279

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual-emission X-ray Absorptiometry
Description: The recruiters were divided into osteoporosis, osteopenia and normal by dual emission X-ray absorptiometry.

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual-emission X-ray Absorptiometry
Description: The recruiters were divided into osteoporosis, osteopenia and normal by dual emission X-ray absorptiometry.

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual-emission X-ray Absorptiometry
Description: The recruiters were divided into osteoporosis, osteopenia and normal by dual emission X-ray absorptiometry.
Study: NCT01608776

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MIST Therapy
Description: The MIST Therapy System is used as a non-contact method of delivering ultrasound to treat chronic wounds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SOC - Standard of Care
Description: Standard of Care includes wound cleansing and debridement as needed, moist wound healing dressings, and offloading
Study: NCT00567346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oralgen
Description: Patients will receive drops of grass pollen immunotherapy sublingually

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oralgen
Description: Patients will receive drops of grass pollen immunotherapy sublingually

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oralgen
Description: Patients will receive drops of grass pollen immunotherapy sublingually

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: grass pollen extract
Description: Patients will receive matching placebo sublingually